Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%) Q1 2026 total net revenue of $34.7 million Reached settlement with Baxter Healthcare Corporation in CINVANTI® patent litigation …